scispace - formally typeset
Open AccessJournal ArticleDOI

Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)

TLDR
This document updates the ARIA sections on the pharmacologic and anti‐IgE treatments of allergic rhinitis and only a few studies assessing nasal and non‐nasal symptoms are presented.
Abstract
The pharmacologic treatment of allergic rhinitis proposed by ARIA is an evidence-based and step-wise approach based on the classification of the symptoms. The ARIA workshop, held in December 1999, published a report in 2001 and new information has subsequently been published. The initial ARIA document lacked some important information on several issues. This document updates the ARIA sections on the pharmacologic and anti-IgE treatments of allergic rhinitis. Literature published between January 2000 and December 2004 has been included. Only a few studies assessing nasal and non-nasal symptoms are presented as these will be discussed in a separate document.

read more

Citations
More filters
Journal ArticleDOI

Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

Jean Bousquet, +95 more
- 01 Apr 2008 - 
TL;DR: The ARIA guidelines for the management of allergic rhinitis and asthma are similar in both the 1999 ARIA workshop report and the 2008 Update as discussed by the authors, but the GRADE approach is not yet available.
Journal ArticleDOI

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision

TL;DR: These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children and patients are encouraged to use these recommendations in their daily practice and to support their decisions.
Journal ArticleDOI

Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

Jean Bousquet, +236 more
TL;DR: Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.
Journal ArticleDOI

Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN.

TL;DR: New evidence supports previous ARIA statements, such as: allergic rhinitis (AR) is a risk factor for asthma, while factors associated with a reduced risk of asthma and AR have been identified, confirming previous findings of protection related to exposure to infections.
Journal ArticleDOI

Positioning of antihistamines in the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines

TL;DR: Oral antihistamines, together with intranasal corticosteroids and leucotriene antagonists, constitute important pharmacological options for the treatment of AR at all levels of severity.
References
More filters
Journal ArticleDOI

Allergic Rhinitis and Its Impact on Asthma

TL;DR: This systematic review and meta-analyses confirmed the findings of a previous study published in “Rhinitis and Asthma: Causes and Prevention, 2nd Ed.” (2015) as well as new findings of “Mechanisms of Respiratory Disease and Allergology,” which confirmed the role of EMTs in the development of these diseases.
Journal ArticleDOI

Allergen immunotherapy: Therapeutic vaccines for allergic diseases A WHO position paper

TL;DR: The document summarizes the scientific literature and rationale for the appropriate use of such therapy to treat allergic rhinoconjunctivitis, allergic asthma, and Hymenoptera hypersensitivity, and offers recommendations for areas of additional and necessary research.
Journal ArticleDOI

Advances in H1-Antihistamines

TL;DR: There are clinically relevant differences among H1-antihistamines in their pharmacology and safety profiles in allergic rhinoconjunctivitis and chronic urticaria.
Journal ArticleDOI

Pharmacy Benefits and the Use of Drugs by the Chronically Ill

TL;DR: The use of medications such as antihistamines and NSAIDs, which are taken intermittently to treat symptoms, was sensitive to co-payment changes, and other medications--antihypertensive, antiasthmatic, antidepressant, antihyperlipidemic, antiulcerant, and antidiabetic agents--also demonstrated significant price responsiveness.
Journal ArticleDOI

Omalizumab-induced reductions in mast cell FcεRI expression and function

TL;DR: Reductions in free IgE levels by omalizumab leads to a rapid reduction in basophil FceRI receptor expression, and the time course for the decrease of Fceri expression in skin mast cells is slower and associated with decreased acute allergen wheal size.
Related Papers (5)

Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

Jean Bousquet, +95 more
- 01 Apr 2008 -